Mirati Therapeutics (MRTX) S-8 Registration of securities for employees

Exhibit 107

Calculation of Filing Fee Table

Form S-8

(Form Type)

Mirati Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

Security Type	Security Class Title	Fee Calculation Rule	Amount Registered(1)	Proposed Maximum Offering Price Per Share	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
Equity	Common Stock, $0.0001 par value per share, 2022 Equity Incentive Plan	Rule 457(c) and Rule 457(h)	11,214,542(2)	$58.01(3)	$650,555,581(3)	0.0000927	$60,306.50
Total Offering Amounts					$650,555,581		$60,306.50
Total Fee Offsets							—
Net Fee Due							$60,306.50

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement shall also cover any additional shares of the Registrant’s Common Stock (the “Common Stock”) that become issuable under the Mirati Therapeutics, Inc.’s 2022 Equity Incentive Plan (the “Plan”) by reason of any stock dividend, stock split, recapitalization or other similar transaction.

(2) Represents (i) 3,500,000 new shares of Common Stock, (ii) 1,294,179 shares of common stock that remained available for grant of new awards under the Mirati Therapeutics, Inc.’s Amended and Restated 2013 Equity Incentive Plan (the “Prior Plan”), and (iii) 6,420,363 shares of Common Stock that were subject to outstanding awards granted under the Prior Plan that may become available for grant under the Plan.

(3) This estimate is made pursuant to Rule 457(h)(1) and Rule 457(c) of the Securities Act solely for purposes of calculating the registration fee. The proposed maximum offering price per share and maximum aggregate offering price are based upon the average of the high and low prices of the Common Stock on May 16, 2022, as reported on The Nasdaq Global Select Market.